BEIJING, Nov. 3 (Xinhua) -- Chinese researchers have made progress in localizing medullary thyroid carcinoma (MTC), a form of thyroid cancer that poses challenges in identifying metastatic lesions.
This post-hoc analysis used a combined cohort of 509 patients with RET-mutated advanced or metastatic medullary thyroid cancer who had received selpercatinib in the two trials. Hadoux reported that ...